NCT06869616

Brief Summary

CRHESO aims at overcoming the considerable burden of mental disorders, which affects both psychosocial well-being and societal welfare, through a multidisciplinary and integrated approach to explore and remediate dimensions affecting social outcome.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
21mo left

Started May 2025

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
May 2025Jan 2028

First Submitted

Initial submission to the registry

February 28, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 11, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

March 11, 2025

Status Verified

March 1, 2025

Enrollment Period

2.5 years

First QC Date

February 28, 2025

Last Update Submit

March 5, 2025

Conditions

Keywords

electrophysiologymetaphor comprehensionlanguage disordersocial functioning

Outcome Measures

Primary Outcomes (8)

  • Analysis of the difference in neurocognitive data between patients and controls

    Tracking down the alteration in neurocognitive abilities, evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) (standardized score 0-4)

    through study completion, an average of 2.5 years

  • Analysis of the difference in sociocognitive data between patients and controls

    Tracking down the alteration in sociocognitive abilities, evaluated with the Picture sequencing task (PST) (score 0-56)

    through study completion, an average of 2.5 years

  • Analysis of the difference in pragmatic data between patients and controls

    Tracking down the alteration in pragmatic abilities, evaluated with Assessment of Pragmatic Abilities and Cognitive Substrates (APACS brief) (score 0-1)

    through study completion, an average of 2.5 years

  • Analysis of the difference in language data between patients and controls

    Tracking down the alteration in language abilities, evaluated with AWechsler Vocabulary task (score 0-66)

    through study completion, an average of 2.5 years

  • Tracking down the difficulties in metaphor comprehension via task during electrophysiological recording

    Exploring the difference in the neurological correlates (via electrophysiological recording technique) between patients and controls. We will measure event-related potential (ERP) after the stimulus presentation

    through study completion, an average of 2.5 years

  • Analysis of the impact of neuropsychological and electrophysiological measures on quality of life

    Evaluate the impact of neuropsychological and electrophysiological measures on quality of life, measured with the Quality of life scale (QLS) (score 0-126)

    through study completion, an average of 2.5 years

  • Analysis of the impact of neuropsychological and electrophysiological measures on community Integration

    Evaluate the impact of neuropsychological and electrophysiological measures on community Integration, measured with the Community Integration measure (CIM) (score 10-50)

    through study completion, an average of 2.5 years

  • Analysis of the impact of neuropsychological and electrophysiological measures on social connectedness

    Evaluate the impact of neuropsychological and electrophysiological measures on social connectedness, measured with the Social Connectedness scale (SCS-R) (score 20-120)

    through study completion, an average of 2.5 years

Secondary Outcomes (8)

  • Evaluation of psychopathology

    through study completion, an average of 2.5 years

  • Evaluate the efficacy of a rehabilitative training in restoring neurocognitive abilities

    through study completion, an average of 2.5 years

  • Evaluate the efficacy of a rehabilitative training in restoring sociocognitive abilities

    through study completion, an average of 2.5 years

  • Evaluate the efficacy of a rehabilitative training in restoring pragmatic abilities

    through study completion, an average of 2.5 years

  • Evaluate the efficacy of a rehabilitative training in restoring language abilities

    through study completion, an average of 2.5 years

  • +3 more secondary outcomes

Study Arms (2)

Schizophrenia Group

We will enroll 50 patients selected according to the presence of Schizophrenia diagnosis (DSM V criteria), which will be tested for metaphor comprehension, as well as for the other variables included in the study, and the electrical brain activity will be registered through a 128 channel EEG. Among these, a subgroup of 10 subjects will undergo a cognitive remediation training (Cognitive Remediation), already published and demonstrated to be feasible for patients with schizophrenia. Specifically, it consists of 15 sessions of 45 minutes each, including computerized domain-specific neurocognitive exercises aimed at training specific cognitive areas known to be impaired in schizophrenia.

Other: Cognitive Remediation

Healthy controls

50 healthy subjects, as control sample, that will be tested for metaphor comprehension, as well as for the other variables included in the study, and the electrical brain activity will be registered through a 128 channel EEG.

Interventions

10 patients will undergo a rehabilitative training (Cognitive Remediation), already published and demonstrated to be feasible for patients with schizophrenia. This program includes domain-specific neurocognitive exercises aimed at training specific cognitive areas known to be impaired in schizophrenia. The treatment plan includes 15 45-minutes sessions.

Schizophrenia Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

50 subjects with schizopnrenia from San Raffaele Hospital (Milan) and 50 healthy controls living in Milan

You may qualify if:

  • Age between 18 and 65 years
  • Diagnosis of Schizophrenia according to DSM V criteria
  • Ability to provide informed consent

You may not qualify if:

  • Intellectual disability
  • Neurological disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Language DisordersSocial Adjustment

Interventions

Cognitive Remediation

Condition Hierarchy (Ancestors)

Communication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsSocial BehaviorBehavior

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Central Study Contacts

Giulia Agostoni, PsyD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PsyD, PhD

Study Record Dates

First Submitted

February 28, 2025

First Posted

March 11, 2025

Study Start

May 1, 2025

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

January 1, 2028

Last Updated

March 11, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share